Ethic Inc. Invests $123,000 in Voyager Therapeutics, Inc. $VYGR

Ethic Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 41,417 shares of the company’s stock, valued at approximately $123,000. Ethic Inc. owned approximately 0.07% of Voyager Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of VYGR. CWM LLC grew its holdings in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after purchasing an additional 9,376 shares during the last quarter. Privium Fund Management B.V. acquired a new stake in shares of Voyager Therapeutics in the 1st quarter worth $73,000. Virtus Advisers LLC purchased a new position in Voyager Therapeutics during the 1st quarter worth $83,000. Invesco Ltd. grew its stake in Voyager Therapeutics by 100.8% during the 1st quarter. Invesco Ltd. now owns 48,540 shares of the company’s stock worth $164,000 after buying an additional 24,368 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Voyager Therapeutics by 53.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company’s stock valued at $204,000 after buying an additional 21,149 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the transaction, the chief financial officer directly owned 123,834 shares in the company, valued at $591,926.52. The trade was a 5.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.39% of the stock is currently owned by corporate insiders.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $4.67 on Friday. The stock has a market cap of $259.04 million, a PE ratio of -2.52 and a beta of 0.95. The firm has a fifty day moving average price of $4.42 and a 200 day moving average price of $3.67. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $7.44.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The company had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. As a group, equities analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Finally, Wedbush dropped their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.96.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.